Neutrabest is pleased to announce that its core technology patents have been officially granted in both the United States and Japan.

These patent registrations recognize Neutrabest’s proprietary designed to effectively inactivate enveloped viruses while maintaining a high level of safety and material compatibility. Securing patent protection in two of the world’s most rigorous intellectual property jurisdictions underscores the technological originality, reliability, and global competitiveness of the Neutrabest platform.

With patent rights now established in the U.S. and Japan, Neutrabest is well positioned to accelerate international partnerships, expand global applications, and further advance its technology across animal health, biosecurity, and industrial hygiene markets.